Archives for 2017

July 19, 2017

ASPYRIAN THERAPEUTICS INC. CLOSES $15.1M AS PART OF A SERIES B-1 FINANCING TO SUPPORT THE ADVANCEMENT OF ITS PROPRIETARY PRECISION TARGETED THERAPY, RM-1929 TO LATE STAGE CLINICAL DEVELOPMENT AND THE PROGRESSION OF NEW PROPRIETARY IMMUNE ONCOLOGY ASSETS INTO THE CLINIC

April 27, 2017

ASPYRIAN ANNOUNCES THE PRESENTATION OF CLINICAL DATA OF ITS INVESTIGATIONAL THERAPY RM-1929 DEMONSTRATING ANTI-CANCER RESPONSE IN RECURRENT HEAD AND NECK CANCER PATIENTS WHO HAVE FAILED ALL EXISTING TREATMENT OPTIONS